Lxbio Pharmaceuticals
Lxbio Pharmaceuticals is a Lisbon-based biopharmaceutical company developing bacteriophage therapies, antibody fragments, and CAR-T cell platforms to treat antibiotic-resistant infections, oncology, and complex pathologies, while operating a CRO laboratory serving pharmaceutical and academic clients.
- Company typePrivate
- Founded2021
- HeadquartersLisbon, Portugal
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lxbio Pharmaceuticals does
Lxbio Pharmaceuticals S.A. is a privately held Portuguese biopharmaceutical company founded in 2021, headquartered in Lisbon, that develops therapeutic platforms targeting antibiotic-resistant infections, oncology, and complex pathologies. Its core technology centers on a proprietary bacteriophage cocktail (five distinct phages targeting Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii) with lead asset TP-102, which received FDA Fast Track Designation for diabetic foot infections and has completed Phase I/IIa clinical trials. The pipeline extends into engineered antibody fragments (Fab, scFv, Nanobodies) for ophthalmology and dermatology indications, nanoparticle-based ocular drug delivery designed to replace invasive intravitreal injections, and a new CAR-T cell and monoclonal antibody development platform.
The company operates a dual business model combining biopharmaceutical product development and Contract Research Organization (CRO) services. On the product side, Lxbio is responsible for worldwide production and commercialization of TP-102 (originating from founding partner TechnoPhage) and other pipeline assets, with planned global distribution anchored by the Bio-Hub consortium infrastructure (Lxbio, TechnoPhage, VectorB2B, and the University of Lisbon Faculty of Pharmacy). On the services side, Lxbio inaugurated the first Iberian Peninsula laboratory dedicated to CAR-T cells and monoclonal antibodies at the University of Lisbon in April 2025, securing T-Oncology as its first international CRO client. The Bio-Hub project carries a €35M total eligible cost with €19M in PRR (Portuguese Recovery and Resilience Plan) incentives, supporting construction of GMP-certified production capacity. Recent capital raises include a €6M investment from Explorer SCR (March 2024) and a 2026 round at a €100 million valuation with IRC and Portugal Panorama Capital funds managed by FundBox.
Lxbio Pharmaceuticals firmographics
Firmographics- Name
- Lxbio Pharmaceuticals
- Legal name
- Lxbio Pharmaceuticals S.A.
- Website
- https://lxbio.pt
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Lxbio Pharmaceuticals is a Lisbon-based biopharmaceutical company developing bacteriophage therapies, antibody fragments, and CAR-T cell platforms to treat antibiotic-resistant infections, oncology, and complex pathologies, while operating a CRO laboratory serving pharmaceutical and academic clients.
- Ownership category
- akta.pro rank
Lxbio Pharmaceuticals industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industry
- mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
Keywords
Where Lxbio Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Lisbon
- HQ country
- Portugal
- HQ region
- Europe
Offices3 records
Markets served
Lxbio Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- CRO Services: Contract Research Organization services providing advanced therapy development support to pharmaceutical companies, start-ups, and academic institutions. The laboratory at University of Lisbon supports transition from pre-clinical research to early clinical development.
- Biopharmaceutical Product Sales: Production and worldwide commercialization of biopharmaceutical products including TP-102 for diabetic foot infections and other pipeline products. The company plans to produce and market innovative biopharmaceuticals globally.
- Licensing and Distribution: Registration, marketing and distribution of biological medicines from Portugal to international markets. The Bio-Hub consortium aims to expand export volume of high value-added biopharmaceutical products.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Lxbio Pharmaceuticals product offering
Product offeringCore offering
Lxbio Pharmaceuticals develops and manufactures biopharmaceutical products based on bacteriophages, recombinant antibody fragments (Fab, scFv, Nanobodies), nanoparticle drug delivery systems, and CAR-T cell therapies, with its lead candidate TP-102 (FDA Fast Track Designation) targeting diabetic foot infections. Through its Advanced Therapies Laboratory, the company also operates as a contract research organization (CRO) providing process development, quality control, and GMP manufacturing services for complex biological products to pharmaceutical companies and academic institutions.
Differentiator
Problem solved
Functional benefit
Products and services
- TP-102 Proprietary bacteriophage-based therapy in clinical development (Phase II/III) for the treatment of diabetic foot infections; received FDA Fast Track Designation in 2025.
- Advanced Therapies Laboratory (CRO Services)
Quantifiable outcome
- Phase I/IIa clinical trial successfully concluded for TP-102 in diabetic foot infections
- +2 more outcomes
Companies that use Lxbio Pharmaceuticals
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Lxbio Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Lxbio Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered major and core.
- T-OncologymajorSwiss company T-Oncology signed as the first international contract for the CAR-T cells and monoclonal antibodies CRO laboratory in Lisbon, underlining the project's global appeal.
- PhageEUcoreLxBio is the first Portuguese biopharmaceutical company to join PhageEU, a Brussels-based coalition aiming to raise the potential of phages in Europe. The mission is to democratize access to phage technology in the European Union, strengthening the community working in industry and academia on phage services and products.
- Portuguese Government (PRR)coreSigning of PRR Grant Agreement with Portuguese Government in scope of Mobilizing Agendas for Business Innovation. The partnership supports the creation of a large-scale plant for biological medicines production with GMP-certified dedicated spaces.
- Bio-Hub Consortium (TechnoPhage, VectorB2B, Faculty of Pharmacy University of Lisbon)coreLxbio leads the Bio-Hub consortium with co-promoters TechnoPhage, VectorB2B, and Faculty of Pharmacy of University of Lisbon. The consortium aims to develop and produce innovative biopharmaceuticals, conduct clinical trials, and implement registration, marketing and distribution from Portugal. Total project cost €35M with €19M PRR incentive.
- TechnophagecoreTechnophage is the founding partner of Lxbio Pharmaceuticals, contributing the TP-102 bacteriophage therapy technology. Lxbio will be responsible for production and worldwide commercialization of TP-102.
- Faculty of Pharmacy, University of LisboncoreAcademic partner in Bio-Hub consortium providing research capabilities and housing the CAR-T cells and monoclonal antibodies laboratory.
Scale indicators7 records
Recent moves8 records
Expansion highlights5 records
Lxbio Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Charles River Laboratories: Large global CRO/CDMO with extensive biologics and cell therapy services. Comparable as a competing CRO platform for advanced therapy development that Lxbio's Lisbon lab is entering.
- Catalent: Global CDMO offering cell therapy and biologics development and manufacturing services. Comparable as a CRO/CDMO competitor for the CAR-T and monoclonal antibody services market Lxbio is targeting.
Direct peers
- Pherecydes Pharma: French clinical-stage biotech developing bacteriophage therapies targeting antibiotic-resistant bacterial infections including Staphylococcus aureus and Pseudomonas aeruginosa. Direct competitor in therapeutic phage cocktails.
- Adaptive Phage Therapeutics: US-based clinical-stage phage therapy company focused on personalized and curated phage treatments for resistant infections. Most advanced US competitor in therapeutic phage development.
- BiomX: Israel-based clinical-stage company developing phage-based therapies for chronic and acute diseases including diabetic foot infection-adjacent indications. Directly comparable modality and clinical-stage profile.
- TechnoPhage: Portuguese biotech and founding partner of Lxbio; develops bacteriophage-based therapeutics and contributed the TP-102 technology to Lxbio. Closest direct peer in phage therapy for bacterial infections.
- Locus Biosciences: Clinical-stage biotech developing engineered phage-based precision antimicrobials (crPhage and Cas3-ARM phage). Comparable in applying engineered phage approaches to resistant bacterial infections.
- ContraFect: US clinical-stage biotech developing direct lytic agents and engineered phage-derived lysins for resistant infections including Staph aureus. Adjacent modality with shared antimicrobial-resistance focus.
Others
- TechnoPhage: Already listed as direct peer; also functions as an enabling technology partner supplying TP-102 bacteriophage assets to Lxbio.
Emerging players
- Eligo Bioscience: French biotech developing phage-based precision medicines using engineered payloads. Overlaps with Lxbio's engineering approach to phage therapy but targets microbiome-based diseases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Lxbio Pharmaceuticals social profiles
Digital presenceLxbio Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lxbio Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles8 records
Lxbio Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lxbio Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lxbio Pharmaceuticals
What does Lxbio Pharmaceuticals do?
Lxbio Pharmaceuticals develops and manufactures biopharmaceutical products based on bacteriophages, recombinant antibody fragments (Fab, scFv, Nanobodies), nanoparticle drug delivery systems, and CAR-T cell therapies, with its lead candidate TP-102 (FDA Fast Track Designation) targeting diabetic foot infections. Through its Advanced Therapies Laboratory, the company also operates as a contract research organization (CRO) providing process development, quality control, and GMP manufacturing services for complex biological products to pharmaceutical companies and academic institutions.
Is Lxbio Pharmaceuticals a public or private company?
Lxbio Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Lxbio Pharmaceuticals founded?
Lxbio Pharmaceuticals was founded in 2021. It employs 1 to 10 people.
Where is Lxbio Pharmaceuticals based?
Lxbio Pharmaceuticals is headquartered in Lisbon, Portugal, in the Europe region.
How does Lxbio Pharmaceuticals make money?
Three revenue lines are on record. CRO Services are the primary driver. The others are biopharmaceutical Product Sales and licensing and Distribution.
Who are Lxbio Pharmaceuticals's main competitors?
Broad incumbents on record are Charles River Laboratories and Catalent. Direct peers are Pherecydes Pharma, Adaptive Phage Therapeutics, BiomX, TechnoPhage, Locus Biosciences and ContraFect. TechnoPhage is listed as an others. Eligo Bioscience is listed as an emerging player.
Does Lxbio Pharmaceuticals have an API?
No public API is recorded for Lxbio Pharmaceuticals.
What industry is Lxbio Pharmaceuticals in?
Lxbio Pharmaceuticals's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 325414 and its SIC code is 2836.